Evidence map›Paper›PMID 30515077›Full record

ArticleFrontiers in molecular neuroscience2018

Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression.

Mario Stampanoni Bassi, Luana Gilio, Pierpaolo Maffei, Ettore Dolcetti, Antonio Bruno, Fabio Buttari, Diego Centonze, Ennio Iezzi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Interleukin 6 SNPGenes · 2022
    Article
  11. Review
  12. Review
  13. Amygdala-hippocampal innervation modulates stress-induced depressive-like behaviors through AMPA receptors.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  14. Review
  15. Chaperone Sigma1R and Antidepressant Effect.International journal of molecular sciences · 2020
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mario Stampanoni BassiUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Luana GilioUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Pierpaolo MaffeiUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Ettore DolcettiLaboratory of Synaptic Immunopathology, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Antonio BrunoLaboratory of Synaptic Immunopathology, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Fabio ButtariUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Diego CentonzeUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Ennio IezziUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Istituto Neurologico Mediterraneo · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The endocannabinoid system (ECS) has been recently recognized as a prominent promoter of the emotional homeostasis, mediating the effects of different environmental signals including rewarding and stressing stimuli. The ECS modulates the rewarding effects of environmental stimuli, influencing synaptic transmission in the dopaminergic projections to the limbic system, and mediates the neurophysiological and behavioral consequences of stress. Notably, the individual psychosocial context is another key element modulating the activity of the ECS. Finally, inflammation represents an additional factor that could alter the cannabinoid signaling in the CNS inducing a "sickness behavior," characterized by anxiety, anhedonia, and depressive symptoms. The complex influences of the ECS on both the environmental and internal stimuli processing, make the cannabinoid-based drugs an appealing option to treat different psychiatric conditions. Although ample experimental evidence shows beneficial effects of ECS modulation on mood, scarce clinical indication limits the use of cannabis-based treatments. To better define the possible clinical indications of cannabinoid-based drugs in psychiatry, a number of issues should be better addressed, including genetic variability and psychosocial factors possibly affecting the individual response. In particular, better knowledge of the multifaceted effects of cannabinoids could help to understand how to boost their therapeutic use in anxiety and depression treatment.

Indexed as

anxietydepressionEAEendocannabinoidsinflammationmultiple sclerosisrewardstress

Identifiers

PMID30515077
PMCPMC6256035
OpenAlexW2901675807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.